ECTRIMS 2023 | Exploring new treatment avenues in MS and beyond

Erik Wallstroem, MD, PhD, Global Head of Development, Neurology and Opthalmology, Sanofi, and Tom Snow, VP, Global Franchise Head, Neurology and Rare Blood Disorders, Sanofi, discuss exciting developments in multiple sclerosis (MS) treatment, emphasizing an under-investigation centrally acting RIPK1 inhibitor. Though still in its Phase II trial, early results are promising, indicating a potential new mode of action for MS treatment. An emerging trend is the interest in the concept of smoldering MS. There’s a consensus in the community about its existence and its impact on patients, underlining a significant unmet need in MS treatment. Looking ahead, there’s hope for new therapeutic options tailored for this subset of patients. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.